Piper Jaffray analyst William Quirk says LabCorp’s Q4 results were in-line with the company’s lowered guidance. Expect to see more deal activity as well as share buy backs with capital allocation priorities shifting in 2019, Quirk tells investors in a post-earnings research note. He believes “most of the bad news” is already reflected in LabCorp’s valuation. As such, he maintains an Overweight rating on the shares with a $177 price target.
https://thefly.com/landingPageNews.php?id=2861149
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.